Initially, we analysed global H3K27me3 levels by flow cytometry in bulk BM cells or various HSPC populations (CD34+CD38−, CD34+CD38+, CD34+) isolated from diagnostic AML BM aspirates from patients who have received standard-of-care induction chemotherapy in a double-blind fashion [13]. The gene discussed is CD34; the disease is acute myeloid leukemia.